
OS Therapies Inc — Investor Relations & Filings
OS Therapies Inc. is a clinical-stage cancer immunotherapy company focused on developing treatments for cancers that express the HER2 protein. The company's approach is to activate the patient's immune system to target and destroy tumor cells. Its lead candidate, OST-HER2, is a therapeutic vaccine initially being developed for osteosarcoma, a type of bone cancer with a significant unmet medical need. The company plans to expand the development of its technology to other HER2-positive solid tumors, including breast, colorectal, esophageal, lung, and ovarian cancers. The pipeline also includes proprietary technologies like OST-tADC Tunable Drug Conjugates.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| QUARTERLY REPORT | 2026-05-18 | English | |
| 424B5 - OS Therapies Inc (0001795091) (Filer) | 2026-04-02 | English | |
| 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | |
| 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | |
| 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | |
| 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
13 filings
| |||||
| 46383305 | QUARTERLY REPORT | 2026-05-18 | English | ||
| 33196663 | 424B5 - OS Therapies Inc (0001795091) (Filer) | 2026-04-02 | English | ||
| 32898412 | 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | ||
| 32898413 | 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | ||
| 32898414 | 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | ||
| 32898415 | 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | ||
| 32898416 | 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | ||
| 32898417 | 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | ||
| 32898418 | 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | ||
| 31749726 | 4 Filing | 2026-02-13 | English | ||
| 31749645 | 8-K Filing | 2026-02-13 | English | ||
| 13219850 | Regulatory Filings 2026 | 2026-01-20 | English | ||
| 13219851 | CURRENT REPORT | 2026-01-12 | English | ||
|
2025
2 filings
| |||||
| 13219852 | Director's Dealing 2025 | 2025-12-20 | English | ||
| 13219853 | Director's Dealing 2025 | 2025-12-20 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Asarina Pharma AB
A biotechnology company in liquidation, formerly focused on…
|
ASAP | SE | Professional, scientific and te… |
|
Atara Biotherapeutics, Inc.
Develops off-the-shelf allogeneic T-cell immunotherapies fo…
|
ATRA | US | Professional, scientific and te… |
|
ATUM CO., LTD.
An integrated biologics development partner offering servic…
|
355690 | KR | Professional, scientific and te… |
|
AUREKA LIMITED
Accelerates drug discovery and development using AI and com…
|
AKA | AU | Professional, scientific and te… |
|
Avalo Therapeutics, Inc.
Clinical-stage biotech developing treatments for immune-med…
|
AVTX | US | Professional, scientific and te… |
|
Avalyn Pharma Inc.
Developing innovative inhaled therapies for rare respirator…
|
AVLN | US | Professional, scientific and te… |
|
Azenta, Inc.
Offers sample management, storage, and multiomics solutions…
|
AZTA | US | Professional, scientific and te… |
|
Baijin Life Science Holdings Limited
An investment holding company operating in biopharmaceutica…
|
1466 | HK | Professional, scientific and te… |
|
BCAL DIAGNOSTICS LIMITED
Developing a non-invasive blood test for early breast cance…
|
BDX | AU | Professional, scientific and te… |
|
BEBETTER MED INC.
Develops small molecule therapeutics for oncology, metaboli…
|
688759 | CN | Professional, scientific and te… |
OS Therapies Inc via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34454/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34454 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34454 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34454 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34454}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for OS Therapies Inc (id: 34454)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.